Dr. Howard Pan
Personalis, Inc. headquartered in Menlo Park California, USA, Was established in 2011 as a Stanford University spin-out by a team of internationally-renown Next Generation Sequencing (NGS) thought leaders to provide advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and cancer immunotherapies by providing more comprehensive molecular data bout each patient’s cancer and immune response. The Personalis ImmunoID NeXT Platform TM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample The Personalis Clinical Laboratory in Menlo Park, Califonria is GxP aligned as well as CLIA’88-certified and CAP-accredited.
On 10 June 2020 Personalis, Inc announced a partnership with Berry Genomics with plans to expand operations in PRC with a wholly-owned subsidiary in Shanghai. Berry will provide sequencing services and local support to Personalis operation in Shanghai. Personalis, Inc was granted approval for a business license for Shanghai Personalis Biotechnology Co, LTD on 15 October 2020. The expansion to China includes buildout of a laboratory operation for local customers to use its ImmunoID Next Platform, a commercial team to support local customers and general and administrative functions.
Personalis
Director of Business DevelopmentAshutosh Parihar
We at Singh Biotechnology (SBT) are interested in meeting with you to exploring possible opportunities for partnering/in-licensing/scientific collaboration.
SBT is a start-up biotech company established in 2014. We discover/develop unique and proprietary therapeutic single domain antibodies (sdAbs) for the treatment of a variety of cancers, autoimmune, ophthalmological, and viral diseases by leveraging our propriety novel technology platform. Using this technology platform SBT has been able to generate therapeutic sdAbs that specifically target intracellular molecules of interest that play an important role in the pathogenesis of disease(s). Our lead therapeutic (SBT-100) is a bi-specific sdAbs that specifically targets and inhibits intracellular KRAS and signal transducer and activator of transcription 3 (STAT3) proteins.
Singh Biotechnology
Vice PresidentYong H. Park
- Focused on developing PD1+ peripheral blood-derived, tumor-reactive CD8+ T cell (PBTL) therapies as a platform for the treatment of solid tumors that are rare, orphan, and have critical (high) unmet need
- PBTL is a simpler, smarter version of TIL
- PBTL is a process to select highly tumor-reactive T cells from a patient's peripheral blood based on the expression of two specific T cell surface markers: PD-1 and/or TIM-3
- After selection, expanded to large quantities, it gets re-infused into the patient via the ACT regimen
- PBTL technology has been patented (issued) already in the US, China, the EU, Japan, Australia
- MEDGENE has robust Clinical Development Pipelines (currently, 9 as monotherapy way)
- Looking for funding for entering Phase I/2 in three pipelines in the US
- Looking for partnering for the Asian market (China, Japan, South Korea)
MedGene Therapeutics
CEOMr. David Platt
Academic study on a small number of patients with the first drug candidate had positive results. The viral load was reduced to zero in all mild/moderate patient after a few days. The drug is not toxic and had no adverse effects. It can prevent spread of infection in 24 hours. It is complementary to vaccination and can prevent infection from close contact. Next step is stage III trials for a bigger group of patients.
We are looking for investors to fund our next phase.
Bioxytran/Pharmalectin
CEODr. Steven Potts
OncoMyx Therapeutics is developing potentially best-in-class (multi-armed, IV/systemically-delivered, precision medicine) oncolytic immunotherapies based upon the myxoma virus (MYXV) platform, and we have demonstrated mechanism of action and combinatorial efficacy (tumor growth inhibition) when dosed IV with various checkpoint inhibitors in multiple animal models. Our company has the industry’s most experienced oncolytic virus (OV) development team and an experienced SAB, and CEO Steve Potts was previously an executive at Ignyta (acquired by Roche for $1.7B). OncoMyx raised a $25M series A in June 2019 to advance our lead preclinical program to IND, and among our investors are BIVF (exited OV investment ViraTx for $244M at preclinical stage in 2018) and Jonathan Lim (Ignyta CEO & current Erasca CEO). On the heels of presenting our preclinical data at SITC and announcing the appointment of Mirati CEO Chuck Baum as our new Chairperson, OncoMyx is seeking a $50M+ series B/crossover to prepare for an IPO and focus on a future transition into a clinical-stage organization. Pasted below are links to our SITC posters and some recent Fierce and BioSpace articles focused on our company.
https://www.oncomyx.com/oncomyx-announces-presentation-of-preclinical-efficacy-data-of-novel-oncolytic-immunotherapy-at-sitc-2020/
https://www.fiercebiotech.com/research/arming-rabbit-pox-virus-to-fight-cancer
https://www.biospace.com/article/oncomyx-s-oncolytic-virus-platform-shows-preclinical-efficacy-boosting-immunotherapy-potential/
OncoMyx Therapeutics
Cofounder, CEO & DirectorFelicia Pullam
- As one of the nation’s largest and fastest growing biotechnology clusters, Maryland is #1 in Ph.D. concentration in biological fields, employed doctoral scientists, and was recognized last year at the 4th best biotechnology cluster in the nation by Genetic Engineering and Biotechnology News.
- We have facilitated access to 74 Federal laboratories, including the National Institutes of Health, the National Institute for Standards and Technology, the Food and Drug Administration, and the Walter Reed Army Institute of Research.
- We can reach 80% of the U.S. pharmaceutical industry and four nearby international airports to enable efficient travel.
- Maryland’s Cost of Doing Business Index is 16%, 12%, and 10% lower than in Boston, New Jersey, and California, respectively, according to Moody’s Analytics Regional Financial Review. In our industry, that translates to a lower cost of operations and wet lab space.
- The cost of living in Maryland can be up to one-and-a-half times lower than in the metropolitan areas of New York, Boston, and San Francisco, according to the Council for Community and Economic Research.